Chemo Therapy - malecare.org

Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.

Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]

By Malecare|2017-10-19T10:53:46-04:00July 20th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Financial, Uncategorized, Understanding APC|18 Comments

Baseline PSA Predicts Risk of Death from Prostate Cancer

The common question when we are diagnosed with prostate cancer is how long do I have to live? The exact same question is asked again when we discover that we have had a prostate cancer recurrence. Times have changed and so has our potential life span. In the late 1980s and early 1990s men diagnosed [...]

By Malecare|2017-10-19T10:53:47-04:00July 15th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, General Information, Prostate Ponderings, Research, Uncategorized, Understanding APC|0 Comments

The Long-Term Survival of Patients with Metastatic Prostate Cancer

Mike Scott who writes the THE “NEW” PROSTATE CANCER INFOLINK today published an excellent summary/discussion about survival time for men with metastatic prostate cancer. He presents a synopsis about anticipated survival going back to the late 1980s and brings the conversation up to our current condition. He reminds us that our next big step will [...]

By Malecare|2020-02-04T10:35:42-05:00July 8th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Drugs & Treatments, General Information, Hormone Therapy, How We Live, MDV3100, Politics of Cancer, Prostate Ponderings, Provenge, Research, Uncategorized, Understanding APC|9 Comments

Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]

By Malecare|2017-10-19T10:53:48-04:00July 6th, 2010|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Research, thalidomide, Uncategorized, Understanding APC|0 Comments

Prostate Cancer SATURN Trial, a Phase 3 Trial in Men with Metastatic Prostate Cancer

A new phase 3, registration trial has been announced by OncoGenex Pharmaceuticals, Inc. of its investigational drug custirsen sodium (OGX-011/TV-1011). The trial, for men with metastatic castrate resistant prostate cancer (mCRPC) is referred to as the Prostate Cancer SATURN Trial. This randomized, controlled, trial will include approximately 50 cancer centers and is planned to enroll [...]

By Malecare|2021-02-22T10:05:36-05:00June 23rd, 2010|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, End-Of-Life, Uncategorized, Understanding APC|0 Comments